Ex vivo nicotine stimulation augments the efficacy of therapeutic bone marrow-derived dendritic cell vaccination

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3706-3712

  Feng, Guang Gao ^a   Da, Fang Wan ^a   Jian, Ren Gu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; INTERLEUKIN 12; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; UPREGULATION;

ANIMALS; ANTIGENS, CD; BONE MARROW CELLS; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; ENDOCYTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, CHEMOKINE; RECEPTORS, NICOTINIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34250715488     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0028     Document Type: Article

References (26)

1. - DC. J Immunol 2006;177:7067-75.
2. Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003;198:1623-6.
3. Reise Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006;6:476-83.
4. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
6. Avila J, Diaz-Nido J. Tangling with hypothermia. Nat Med 2004;10:460-1.
7. Mandavilli A. Nicotine fix. Nat Med 2004;10:660-1.
8. Libert C. Inflammation-a nervous connection. Nature 2003;421:328-9.
9. Wessler IK, Kirkpatrick CJ. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther 2001;14:423-34.
10. Guinet E, Yoshida K, Nouri-Shirazi M. Nicotinic environment affects the differentiation and functional maturation of monocytes derived dendritic cells (DCs). Immunol Lett 2004;95:45-55.
11. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 2005;175:2684-91.
12. Aicher A, Heeschen C, Mohanpt M, Cooke JP, Zeiher AM, Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity - potential role for progression of atherosclerotic lesions. Circulation 2003;107:604-11.
13. Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003;109:365-73.
14. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor α7 subunits is an essential regulator of inflammation. Nature 2003;421:384-8.
15. Matsunaga K, Klein TW, Friedman H, Yamamoto Y. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 2001;167:6518-24.
16. Zhang MH, Tang H, Guo ZH, et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 2004;5:1124-33.
17. + Tcell to a fully functional tumor killer cell. Cancer Res 2002;62:6438-41.
18. Hanna ST. Nicotine effect on cardiovascular system and ion channels. J Cardiovasc Pharmacol 2006;47:348-58.
19. Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 2003;74:675-96.
20. Middlebrook AJ, Martina C, Chang Y, Lukas RJ, Deluca D. Effects of nicotine exposure on T cell development in fetal thymus organ culture: arrest of T cell maturation. J Immunol 2002;169:2915-24.
21. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nat Med 1998;4:328-32.
22. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
23. + Tc1 responses in vivo. Eur J Immunol 2004;34:66-73.
24. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191:1777-88.
25. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004;10:887-92.
26. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116:2208-17.